ALLERGY THERAPEUTICS PLC

Major Shareholding Notification • Nov 27, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2532H

Allergy Therapeutics PLC

27 November 2015

For filings with the FCA include the annex
For filings with issuer exclude the annex
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii												Allergy Therapeutics plc
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights																	X
Other (please specify):
3. Full name of person(s) subject to the notification obligation: iii									Abbott Laboratories
4. Full name of shareholder(s) (if different from 3.):iv									CFR lnternational SpA Yissum Holding Limited
5. Date of the transaction and date on which the threshold is crossed or reached: v									20 November 2015
6. Date on which issuer notified:									20 November 2015
7. Threshold(s) that is/are crossed or reached: vi, vii									Below 41%
8. Notified details:
A: Voting rights attached to shares viii, ix
Class/type of shares if possible using the ISIN CODE	Situation previous to the triggering transaction							Resulting situation after the triggering transaction
Number of Shares				Number of Voting Rights			Number of shares				Number of voting rights		% of  voting rights x
Direct				Direct xi	Indirect xii	Direct		Indirect
Ord GBP 0.01	240,584,571				240,584,571								240,584,571			40.995%
GB00B02LCQ05
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument				Expiration date xiii		Exercise/ Conversion Period xiv						Number of voting rights that may be acquired if the instrument is exercised/ converted.			% of voting rights
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial instrument		Exercise price			Expiration date xvii		Exercise/ Conversion period xviii					Number of voting rights instrument refers to			% of voting rights xix, xx
															Nominal		Delta
Total (A+B+C)
Number of voting rights										Percentage of voting rights
240,584,571										40.995%
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi
Through a series of controlled undertakings, Abbott Laboratories has an indirect holding of 99.9% of the shares in CFR Pharmaceuticals, SA. CFR Pharmaceuticals SA's wholly owned subsidiary, CFR International SPA, holds 17.567% of the voting rights in Allergy Therapeutics plc directly and 23.428% of the voting rights in Allergy Therapeutics plc indirectly. CFR International SPA also has a 100% interest in Yissum Holding Limited, which directly holds 23.428% of shares in Allergy Therapeutics plc.
Proxy Voting:
10. Name of the proxy holder:
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:
13. Additional information:
14. Contact name:										Des Peters
15. Contact telephone number:										+1 224-667-6545

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLUBAVRVBAAUAA